Array BioPharma Inc.
This article was originally published in Start Up
Amgen Boulder's medicinal chemists have launched a start-up of their own-Array BioPharma Inc., a "medicinal chemistry strike force." Array is positioning itself as a lead optimization team for hire at the preclinical bottleneck faced by companies that have internalized biotech's mass compound generation technologies
You may also be interested in...
While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.
While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.
The trend of biopharma IPOs eschewing Nasdaq for European and other exchanges reverses modestly in 2006.